These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 35887001)

  • 1. JIB-04, a Pan-Inhibitor of Histone Demethylases, Targets Histone-Lysine-Demethylase-Dependent AKT Pathway, Leading to Cell Cycle Arrest and Inhibition of Cancer Stem-Like Cell Properties in Hepatocellular Carcinoma Cells.
    Lee J; Kim JS; Cho HI; Jo SR; Jang YK
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JIB-04, A Small Molecule Histone Demethylase Inhibitor, Selectively Targets Colorectal Cancer Stem Cells by Inhibiting the Wnt/β-Catenin Signaling Pathway.
    Kim MS; Cho HI; Yoon HJ; Ahn YH; Park EJ; Jin YH; Jang YK
    Sci Rep; 2018 Apr; 8(1):6611. PubMed ID: 29700375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
    Bayo J; Fiore EJ; Dominguez LM; Real A; Malvicini M; Rizzo M; Atorrasagasti C; García MG; Argemi J; Martinez ED; Mazzolini GD
    J Hepatol; 2019 Jul; 71(1):78-90. PubMed ID: 30880225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JIB-04, a histone demethylase Jumonji C domain inhibitor, regulates phenotypic switching of vascular smooth muscle cells.
    He Y; Yi X; Zhang Z; Luo H; Li R; Feng X; Fang ZM; Zhu XH; Cheng W; Jiang DS; Zhao F; Wei X
    Clin Epigenetics; 2022 Aug; 14(1):101. PubMed ID: 35964071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.
    Banelli B; Daga A; Forlani A; Allemanni G; Marubbi D; Pistillo MP; Profumo A; Romani M
    Oncotarget; 2017 May; 8(21):34896-34910. PubMed ID: 28432280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analyses of prognostic biomarkers and immune infiltrates among histone lysine demethylases (KDMs) in hepatocellular carcinoma.
    Qu LH; Fang Q; Yin T; Yi HM; Mei GB; Hong ZZ; Qiu XB; Zhou R; Dong HF
    Cancer Immunol Immunother; 2022 Oct; 71(10):2449-2467. PubMed ID: 35254477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting PI3K/Akt/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment.
    Kahraman DC; Kahraman T; Cetin-Atalay R
    Mol Cancer Ther; 2019 Nov; 18(11):2146-2157. PubMed ID: 31439713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth.
    Wang L; Chang J; Varghese D; Dellinger M; Kumar S; Best AM; Ruiz J; Bruick R; Peña-Llopis S; Xu J; Babinski DJ; Frantz DE; Brekken RA; Quinn AM; Simeonov A; Easmon J; Martinez ED
    Nat Commun; 2013; 4():2035. PubMed ID: 23792809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KDM5B regulates the PTEN/PI3K/Akt pathway to increase sorafenib-resistance in hepatocellular carcinoma.
    Liu J; Nie C
    Anticancer Drugs; 2022 Oct; 33(9):840-849. PubMed ID: 35946516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
    Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
    Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone demethylase JMJD2D promotes the self-renewal of liver cancer stem-like cells by enhancing EpCAM and Sox9 expression.
    Deng Y; Li M; Zhuo M; Guo P; Chen Q; Mo P; Li W; Yu C
    J Biol Chem; 2021; 296():100121. PubMed ID: 33434575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathway.
    Liu JS; Huo CY; Cao HH; Fan CL; Hu JY; Deng LJ; Lu ZB; Yang HY; Yu LZ; Mo ZX; Yu ZL
    Phytomedicine; 2019 Aug; 61():152843. PubMed ID: 31039533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
    Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumorspheres Derived from HCC Cells are Enriched with Cancer Stem Cell-like Cells and Present High Chemoresistance Dependent on the Akt Pathway.
    Zhang XL; Jia Q; Lv L; Deng T; Gao J
    Anticancer Agents Med Chem; 2015; 15(6):755-63. PubMed ID: 25642979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Jumonji Histone Demethylase Inhibitor JIB-04 as a Broad-Spectrum Antifungal Agent.
    Wang T; Yang W; Liu Y; Li W; Wang Y; Liu N; Sheng C
    ACS Infect Dis; 2022 Jul; 8(7):1316-1323. PubMed ID: 35695031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Connexin32 regulates expansion of liver cancer stem cells via the PI3K/Akt signaling pathway.
    Li H; Wang B; Qi B; Jiang G; Qin M; Yu M
    Oncol Rep; 2022 Sep; 48(3):. PubMed ID: 35894130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KDM6B Counteracts EZH2-Mediated Suppression of
    Wang W; Lim KG; Feng M; Bao Y; Lee PL; Cai Y; Chen Y; Zhang H; Marzese D; Hoon DSB; Yu Q
    Mol Cancer Ther; 2018 Sep; 17(9):1973-1983. PubMed ID: 29925528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15.
    Duan L; Perez RE; Calhoun S; Maki CG
    Cancer Biol Ther; 2022 Dec; 23(1):65-75. PubMed ID: 35100078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
    Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
    J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of the
    Matthews KA; Senagbe KM; Nötzel C; Gonzales CA; Tong X; Rijo-Ferreira F; Bhanu NV; Miguel-Blanco C; Lafuente-Monasterio MJ; Garcia BA; Kafsack BFC; Martinez ED
    ACS Infect Dis; 2020 May; 6(5):1058-1075. PubMed ID: 32272012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.